skin medicine under trademarks including trademark of “DERMALIS”, (which will be Criterion Calculation Method Transaction size 1. Net tangible assets (NTA) Proportion of assets acquired (100%) x NTA AT

5.8 Manufacture and skincare products, cosmetics, food supplements and medicine used to treat skin diseases segment 9,708 2.2 13,124 3.2 (3,416) (26.0) total 443,248 100.0 417,617 100.0 25,631 6.1 The

more revenue contribution from IPD which generated highest margin comparing to other categories. Moreover, the efficient cost management such as medicine & medical supplies as well as the benefit from

security patients which generated high margin and effect of increase of social security payment rate in 1H’18. Moreover, the efficient cost management such as medicine & medical supplies as well as the

medicine and supplies as well as staff. Administrative Expenses Administrative expenses increased dramatically by 24% yoy. This was the result of aforementioned provision for employee benefit of THB 2.2

operations for 2nd Quarter of 2017 decreased to 71.69%, while it was 74.38% for the 2nd Quarter of 2016. These resulted from the efficiency of medicine and medical supplies cost management, introducing an

million of 1Q20. The normalized profit has decreased by 15% yoy. Page 3 of 4 Statement of Financial Position as of March 31, 2020 The consolidated total assets as of 31 March 2020 increased from end of

Laboratories Co., Ltd. is a listed company established in the year 1971. The manufacture and distribution of conventional medicine. Office and Factory are located at No.47 Soi Boonchana, Sukhumvit 59, Klong Ton

of December 31, 2019 The consolidated total assets as of 31 December 2019 decreased by 10% yoy. The decrease was mainly attributable to cash spending on loan repayment as well as investment not only in

increased significantly by 19. 4% yoy with the margin improved from 17.4% to 19.2%. Page 3 of 4 Statement of Financial Position as of September 30, 2019 The consolidated total assets as of 30 September 2019